Tumour infiltrating lymphocytes - Iovance Biotherapeutics/University of Texas M.D. Anderson Cancer Center

Drug Profile

Tumour infiltrating lymphocytes - Iovance Biotherapeutics/University of Texas M.D. Anderson Cancer Center

Alternative Names: Adoptive T cell therapy - Iovance Biotherapeutics/University of Texas M.D. Anderson Cancer Center; TIL - Iovance Biotherapeutics/University of Texas M.D. Anderson Cancer Center

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Iovance Biotherapeutics
  • Developer Iovance Biotherapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Ovarian cancer; Pancreatic cancer; Sarcoma

Most Recent Events

  • 24 Aug 2017 Phase-I clinical trials in Ovarian cancer, Pancreatic cancer and Sarcoma in USA (Parenteral) (Iovance Biotherapeutics pipeline, August 2017)
  • 24 Aug 2017 Iovance Biotherapeutics and University of Texas M.D. Anderson Cancer Center plans to initiate a phase II trial of Tumour infiltrating lymphocytes in Ovarian cancer, Pancreatic cancer and Sarcoma in December 2017 (Iovance Biotherapeutics pipeline, August 2017)
  • 19 Apr 2017 Lion Biotechnologies (now Iovance Biotherapeutics) enters into a strategic alliance with University of Texas M.D. Anderson Cancer Center to conduct clinical trials of tumour-infiltrating lymphocytes in multiple solid tumours, including ovarian, pancreatic and sarcoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top